Lumateperone

Brand names: Caplyta · Active ingredient: Lumateperone

In short: CAPLYTA is indicated for: Treatment of schizophrenia in adults . Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate .

Forms & strengthsCAPLYTA capsules are available in three strengths: 42 mg: Blue cap and opaque white body imprinted with “ITI-007 42 mg” 21 mg: Opaque white cap and body imprinted with “ITI-007 21 mg” 10.5 mg: Opaque light pink cap and body imprinted with “ITI-007 10.5 mg”
LabelIntra-Cellular Therapies, Inc
Label updatedNov 09, 2026

What is Lumateperone used for?

CAPLYTA is indicated for:

Treatment of schizophrenia in adults .

Treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate .

Adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults .

⚠ Boxed warning (FDA's strongest warning)

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. CAPLYTA

is not approved for the treatment of patients with dementia-related psychosis .

Suicidal Thoughts and Behaviors

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors . The safety and effectiveness of CAPLYTA have not been established in pediatric patients .

Lumateperone dosage

The recommended CAPLYTA dosage is 42 mg administered orally once daily with or without food. Dose titration is not needed.

The recommended CAPLYTA dosage in patients who receive :

Strong CYP3A4 inhibitors is 10.5 mg once daily.

Moderate CYP3A4 inhibitors is 21 mg once daily.

For patients with moderate hepatic impairment (HI) (Child-Pugh class B) or severe HI (Child-Pugh class C), the recommended CAPLYTA dosage is 21 mg once daily . The recommended CAPLYTA dosage in patients with mild HI is the same as those with normal hepatic function.

How to take Lumateperone — instructions & advice from the label

Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide).

Suicidal Thoughts and Behavior

Advise patients and caregivers to look for the emergence of suicidal thoughts and behaviors, especially early during CAPLYTA treatment and instruct them to report such symptoms to their healthcare provider .

Neuroleptic Malignant Syndrome

Counsel patients about a potentially fatal neuroleptic malignant syndrome (NMS), that has been reported with administration of antipsychotic drugs. Advise patients, family members, or caregivers to contact the healthcare provider or to report to the emergency room if they experience signs and symptoms of NMS .

Tardive Dyskinesia

Counsel patients on the signs and symptoms of tardive dyskinesia and to contact their healthcare provider if these abnormal movements occur .

Metabolic Changes

Educate patients about the risk of metabolic changes, how to recognize symptoms of hyperglycemia and diabetes mellitus, and the need for specific monitoring, including blood glucose, lipids, and weight . …

Warnings & precautions

Do not take this medicine if: CAPLYTA is contraindicated in patients with history of hypersensitivity reaction to lumateperone or any components of CAPLYTA. Reactions have included pruritus, rash (e.g. allergic dermatitis, papular rash, and generalized rash), and urticaria.

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. In an analysis of 17 placebo-controlled trials (modal duration of 10 weeks), largely in patients taking atypical antipsychotic drugs, the risk of death in antipsychotic drug-treated patients was 1.6 to 1.7 times the risk of death in placebo-treated patients. Over the course of a typical 10-week controlled trial, the incidence of death in antipsychotic-treated patients was about 4.5%, compared to an incidence of about 2.6% in placebo-treated patients. Although the causes of death varied, most of the deaths appeared to be either cardiovascular (e.g., heart failure, sudden death) or infectious (e.g., pneumonia).

CAPLYTA is not approved for the treatment of patients with dementia-related psychosis .

In pooled analyses of placebo-controlled trials of antidepressant drugs (SSRIs and other antidepressant classes) that included approximately 77,000 adult patients and 4,500 pediatric patients, the incidence of suicidal thoughts and behaviors in antidepressant-treated pediatric and young adult patients was greater than in placebo-treated patients. There were differences in absolute risk of suicidal thoughts and behaviors across the different uses, with the highest incidence in patients with MDD. The drug-placebo differences in the number of cases of suicidal thoughts and behaviors per 1,000 patients treated are provided in Table 1. …

Lumateperone side effects

The following adverse reactions are discussed in detail in other sections of the labeling:

Increased Mortality in Elderly Patients with Dementia-Related Psychosis

Suicidal Thoughts and Behaviors

Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-related Psychosis

Neuroleptic Malignant Syndrome

Tardive Dyskinesia

Metabolic Changes

Leukopenia, Neutropenia, and Agranulocytosis

Orthostatic Hypotension and Syncope

Falls

Seizures

Potential for Cognitive and Motor Impairment

Body Temperature Dysregulation

Dysphagia

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of CAPLYTA has been evaluated in placebo-controlled clinical trials that included 3575 adult patients with schizophrenia, bipolar depression, or major depressive disorder, exposed to one or more CAPLYTA doses. A total of 852 CAPLYTA-treated patients had at least 6 months of treatment and 108 had at least 1 year of treatment with the 42-mg once daily dosage.

Adverse Reactions in Patients with Schizophrenia

The following adverse reactions are based on the pooled short-term (4- to 6-week), placebo-controlled studies in adult patients with schizophrenia in which CAPLYTA was administered at a dosage of 42 mg once daily (N=406) . …

Drug interactions

Clinically important drug interactions with CAPLYTA are presented in Table 6.

CYP3A4 Inducers*

Prevention or Management | Avoid concomitant use of CAPLYTA with CYP3A4 inducers.

Clinical Impact | Concomitant use of CAPLYTA with CYP3A4 inducers decreases the exposure of lumateperone .

Moderate or Strong CYP3A4 Inhibitors*

Prevention or Management | Reduce the CAPLYTA dosage when used concomitantly with moderate or strong CYP3A4 inhibitors .

Clinical Impact | Concomitant use of CAPLYTA with moderate or strong CYP3A4 inhibitors increases lumateperone exposure , which may increase the risk of adverse reactions.

Serotonin Reuptake Inhibitors

Prevention or Management | Increased monitoring for SRI- associated adverse reactions is recommended.

Clinical Impact | Although no clinically significant drug interactions with adjunctive SSRI/SNRIs in MDD were observed in CAPLYTA clinical trials, CAPLYTA’s moderate serotonin transporter (SERT) activity may increase the risk of SRI-associated adverse reactions (e.g., serotonin syndrome, hyponatremia).

* See www.fda.gov/CYPandTransporterInteractingDrugs for examples of CYP3A4 Inducers and Moderate or Strong CYP3A4 Inhibitors

About this medicine

Lumateperone is an atypical antipsychotic present as lumateperone tosylate salt with the chemical name 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluoro-phenyl)-butan-1-one 4-methylbenzenesulfonate. Its molecular formula is C31H36FN3O4S, and its molecular weight is 565.71 g/mol with the following structure:

CAPLYTA (lumateperone) capsules are for oral administration. Each capsule contains:

42 mg of lumateperone (equivalent to 60 mg of lumateperone tosylate), or

21 mg of lumateperone (equivalent to 30 mg of lumateperone tosylate), or

10.5 mg of lumateperone (equivalent to 15 mg of lumateperone tosylate).

The capsules include the following inactive ingredients: croscarmellose sodium, gelatin, magnesium stearate, mannitol, and talc. Colorants include FD&C blue #1 and red #3 (42 mg), FDA/E172 black iron oxide, FDA/E172 red iron oxide and FD&C red #3 (10.5 mg), and titanium dioxide (42 mg, 21 mg and 10.5 mg). …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID db730b06-6351-47fd-8183-e61e61bbead5. Read the full official label on DailyMed.

Related medicines

Sertraline Escitalopram Bupropion Fluoxetine Trazodone Duloxetine Prednisone Buspirone